Neratinib led to a statistically significant improvement in centrally confirmed progression-free survival compared with lapatinib and capecitabine in patients with HER2-positive metastatic breast cancer who have failed 2 or more prior lines of HER2-directed therapy.
Ciara O’Sullivan, MB, BCh, discusses the need for treatment de-escalation for patients with HER2-positive breast cancer, as well as the challenges that remain in tailoring treatment.
Akihiko Shimomura, MD, PhD, discusses the rationale for the phase III HERB TEA trial of elderly patients with HER2-positive breast cancer.
Shannon L. Puhalla, MD, discusses some of the advances being made in systemic treatment for patients with brain metastases from breast cancer.
In patients with early-stage HER2-positive breast cancer who are being treated with adjuvant trastuzumab and anthracyclines, cardiotoxicity-free survival is longer when they receive prophylactic simultaneous lisinopril or carvedilol.
The combination of palbociclib and trastuzumab demonstrated safety and efficacy in patients with advanced estrogen receptor–positive/HER2-positive breast cancer.
Ado-trastuzumab emtansine reduced the risk of invasive disease recurrence or death by 50% compared with trastuzumab as an adjuvant treatment for patients with HER2-positive early breast cancer who had residual invasive disease following neoadjuvant therapy.
Vik Gorantla, MD, discusses ongoing developments in the adjuvant setting for patients with HER2-positive breast cancer.
Data from the NSABP B-52, PERSEPHONE, and APT trials have called into question the optimal duration of treatment for patients with HER2-positive breast cancer.
Mohammed Rahman, MD, discusses ongoing efforts to optimize the use of neratinib in patients with HER2-positive breast cancer.